帕博利珠-话题@MedSci

#帕博利珠#

54篇内容 | 1079人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2056864, encodeId=f262205686458, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=肝癌免疫治疗前景广阔，帕博利珠单抗对亚洲人群疗效更佳, objectType=article, longId=177173, objectId=26071e71735c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26071e71735c, replyNumber=0, likeNumber=38, createdTime=2020-05-23, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26071e71735c, moduleTitle=肝癌免疫治疗前景广阔，帕博利珠单抗对亚洲人群疗效更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26071e71735c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056858, encodeId=9051205685801, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益, objectType=article, longId=168158, objectId=24ab168158c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24ab168158c3, replyNumber=0, likeNumber=0, createdTime=2019-10-07, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24ab168158c3, moduleTitle=帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24ab168158c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056871, encodeId=46a420568e188, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=喜大普奔！帕博利珠单抗联合化疗一线治疗转移性鳞状非小细胞肺癌在华获批, objectType=article, longId=184012, objectId=576f184012f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=576f184012f8, replyNumber=0, likeNumber=37, createdTime=2020-10-30, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=576f184012f8, moduleTitle=喜大普奔！帕博利珠单抗联合化疗一线治疗转移性鳞状非小细胞肺癌在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=576f184012f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056859, encodeId=b64d205685949, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗联合化疗一线治疗非鳞非小细胞肺癌, objectType=article, longId=168266, objectId=244716826602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=244716826602, replyNumber=0, likeNumber=39, createdTime=2019-07-10, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=244716826602, moduleTitle=帕博利珠单抗联合化疗一线治疗非鳞非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=244716826602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056865, encodeId=c547205686590, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=复旦大学附属中山医院刘天舒教授谈帕博利珠单抗获批食管癌之研究亮点与临床意义, objectType=article, longId=178511, objectId=1a891e851168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a891e851168, replyNumber=0, likeNumber=33, createdTime=2020-07-24, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a891e851168, moduleTitle=复旦大学附属中山医院刘天舒教授谈帕博利珠单抗获批食管癌之研究亮点与临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a891e851168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056868, encodeId=5b372056868a7, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗联合化疗用于早期TNBC新辅助治疗pCR率达到64.8%, objectType=article, longId=180890, objectId=59ac18089033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ac18089033, replyNumber=0, likeNumber=45, createdTime=2019-12-29, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ac18089033, moduleTitle=帕博利珠单抗联合化疗用于早期TNBC新辅助治疗pCR率达到64.8%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59ac18089033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056867, encodeId=8eb0205686e63, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, objectType=article, longId=180793, objectId=fd6a180e93a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd6a180e93a8, replyNumber=0, likeNumber=38, createdTime=2020-01-27, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd6a180e93a8, moduleTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd6a180e93a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056857, encodeId=ecd1205685eee, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗或为晚期胃癌一线治疗提供新选择, objectType=article, longId=167950, objectId=1d9b16e95039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d9b16e95039, replyNumber=0, likeNumber=38, createdTime=2019-11-23, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d9b16e95039, moduleTitle=帕博利珠单抗或为晚期胃癌一线治疗提供新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d9b16e95039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056856, encodeId=6ee8205685635, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Lancet Oncol：阿昔替尼联合帕博利珠单抗治疗晚期肉瘤，PFS率远超历史, objectType=article, longId=166056, objectId=9bff16605624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bff16605624, replyNumber=0, likeNumber=29, createdTime=2019-06-10, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bff16605624, moduleTitle=Lancet Oncol：阿昔替尼联合帕博利珠单抗治疗晚期肉瘤，PFS率远超历史, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bff16605624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056854, encodeId=41152056854cb, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=【2018 ESMO】KEYNOTE-057研究：卡介苗治疗无效的高风险非肌层浸润性膀胱癌，帕博利珠单抗显疗效, objectType=article, longId=152388, objectId=65e815238817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e815238817, replyNumber=0, likeNumber=47, createdTime=2019-03-17, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e815238817, moduleTitle=【2018 ESMO】KEYNOTE-057研究：卡介苗治疗无效的高风险非肌层浸润性膀胱癌，帕博利珠单抗显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e815238817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056851, encodeId=ac1420568518d, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Lancet:并非所有的免疫治疗都能创造奇迹——帕博利珠单抗未能延长胃/胃食管结合部癌症患者总生存, objectType=article, longId=141137, objectId=499714113ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=499714113ec6, replyNumber=0, likeNumber=34, createdTime=2018-08-13, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=499714113ec6, moduleTitle=Lancet:并非所有的免疫治疗都能创造奇迹——帕博利珠单抗未能延长胃/胃食管结合部癌症患者总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=499714113ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056853, encodeId=4fdc2056853b2, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Lung Cancer：帕博利珠单抗作为晚期NSCLC一线治疗的成本效果, objectType=article, longId=151819, objectId=910e151819fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=910e151819fd, replyNumber=0, likeNumber=23, createdTime=2019-01-02, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=910e151819fd, moduleTitle=Lung Cancer：帕博利珠单抗作为晚期NSCLC一线治疗的成本效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=910e151819fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056852, encodeId=b1262056852af, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=【NCCN更新】帕博利珠单抗联合化疗——晚期肺鳞癌患者一线治疗新选择, objectType=article, longId=147733, objectId=907414e73367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=907414e73367, replyNumber=0, likeNumber=29, createdTime=2019-06-13, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=907414e73367, moduleTitle=【NCCN更新】帕博利珠单抗联合化疗——晚期肺鳞癌患者一线治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=907414e73367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056855, encodeId=dbaf2056855c9, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, objectType=article, longId=152644, objectId=1a4c15264424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a4c15264424, replyNumber=0, likeNumber=28, createdTime=2019-06-23, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a4c15264424, moduleTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a4c15264424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056850, encodeId=0d3d205685068, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Oncologist：一例dMMR及种系BRAC1突变子宫内膜癌患者使用帕博利珠单抗达到完全缓解的病例报告, objectType=article, longId=131804, objectId=238713180436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=238713180436, replyNumber=0, likeNumber=36, createdTime=2018-04-20, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=238713180436, moduleTitle=Oncologist：一例dMMR及种系BRAC1突变子宫内膜癌患者使用帕博利珠单抗达到完全缓解的病例报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=238713180436)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

帕博利珠

2020-05-29

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

肝癌免疫治疗前景广阔，帕博利珠单抗对亚洲人群疗效更佳

2020-05-23

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益

2019-10-07

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

喜大普奔！帕博利珠单抗联合化疗一线治疗转移性鳞状非小细胞肺癌在华获批

2020-10-30

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗联合化疗一线治疗非鳞非小细胞肺癌

2019-07-10

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

复旦大学附属中山医院刘天舒教授谈帕博利珠单抗获批食管癌之研究亮点与临床意义

2020-07-24

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗联合化疗用于早期TNBC新辅助治疗pCR率达到64.8%

2019-12-29

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好

2020-01-27

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗或为晚期胃癌一线治疗提供新选择

2019-11-23

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Lancet Oncol：阿昔替尼联合帕博利珠单抗治疗晚期肉瘤，PFS率远超历史

2019-06-10

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

【2018 ESMO】KEYNOTE-057研究：卡介苗治疗无效的高风险非肌层浸润性膀胱癌，帕博利珠单抗显疗效

2019-03-17

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Lancet:并非所有的免疫治疗都能创造奇迹——帕博利珠单抗未能延长胃/胃食管结合部癌症患者总生存

2018-08-13

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Lung Cancer：帕博利珠单抗作为晚期NSCLC一线治疗的成本效果

2019-01-02

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

【NCCN更新】帕博利珠单抗联合化疗——晚期肺鳞癌患者一线治疗新选择

2019-06-13

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著

2019-06-23

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Oncologist：一例dMMR及种系BRAC1突变子宫内膜癌患者使用帕博利珠单抗达到完全缓解的病例报告

2018-04-20

科室
- - 订阅+
  - 更多科室
工具
服务